KalVista Pharmaceuticals (KALV) Tops Q1 EPS by 14c

KalVista Pharmaceuticals (NASDAQ: KALV) reported Q1 EPS of ($0.74), $0.14 better than the analyst estimate of ($0.88).

For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS Upgrades Apollo Tyres (APTY:IN) to Buy
• Beike (BEKE) PT Raised to $23 at Morgan Stanley